ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

In Brief: House Bill Boosts NIH Funding By $1.2 Billion; ASCO Counted More Than 17,000 Registrants

June 26, 1998

In Brief: Senate Tracks Reauthorization n New Institute Bill, Waxman May Go Along: Abe Goldin Dies

August 19, 1988

Graalman Objects To Criticism On Contract Competition

April 22, 1977

Treanda Approved For B-Cell Non-Hodgkin’s Lymphoma

October 31, 2008

DCT Board Okays Consideration Of New New Heavy Particle Therapy Studies

March 8, 1985

In Brief: Lippman Leads M.D. Anderson Clinical Prevention; Baylin Named Ludwig Professor

May 10, 1996